Company description

Cidara Therapeutics, Inc. (CDTX) is a biotechnology company based in San Diego, California. Founded in 2014, the company focuses on developing innovative therapies for serious and life-threatening fungal infections. Cidara's unique approach to treatment involves using the body's immune system to fight infections, rather than relying solely on traditional antibiotics. The company's flagship product, rezafungin, has shown promise in treating a wide range of fungal infections, including those that are resistant to current therapies. Cidara also has a rich pipeline of other potential treatments in various stages of development, making it a leader in the fight against fungal infections. With a dedicated team of experienced scientists and executives, Cidara is committed to bringing life-saving treatments to patients in need. As a publicly-traded company on the Nasdaq market, Cidara continues to garner attention from investors and researchers alike for its groundbreaking work in the field of antifungal therapies.